miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer.1

Abstract

MicroRNAs (miRNAs) are short single-stranded RNAs, measuring 21 to 23 nucleotides in length and regulate gene expression at the post-transcriptional level through mRNA destabilization or repressing protein synthesis. Dysregulation of miRNAs can lead to tumorigenesis through changes in regulation of key cellular processes such as cell proliferation, cell survival, and apoptosis. miR-125a-5p has been implicated as a tumor suppressor miRNA in malignancies such as non-small cell lung cancer and colon cancer. However, the role of miR-125a-5p has not been fully investigated in head and neck squamous cell carcinoma (HNSCC). We performed microRNA microarray profiling of HNSCC tumor samples obtained from a prospective clinical trial evaluating the role of postoperative radiotherapy in head and neck cancer. We also mined through The Cancer Genome Atlas to evaluate expression and survival data. Biological experiments, including cell proliferation, flow cytometry, cell migration and invasion, clonogenic survival, and fluorescent microscopy, were conducted using HN5 and UM-SCC-22B cell lines. miR-125a-5p downregulation was associated with recurrent disease in a panel of high-risk HNSCC and then confirmed poor survival associated with low expression in HNSCC via the Cancer Genome Atlas, suggesting that miR-125a-5p acts as a tumor suppressor miRNA. We then demonstrated that miR-125a-5p regulates cell proliferation through cell cycle regulation at the G1/S transition. We also show that miR-125a-5p can alter cell migration and modulate sensitivity to ionizing radiation. Finally, we identified putative mRNA targets of miR-125a-5p, including ERBB2, EIF4EBP1, and TXNRD1, which support the tumor suppressive mechanism of miR-125a-5p. Functional validation of ERBB2 suggests that miR-125a-5p affects cell proliferation and sensitivity to ionizing radiation, in part.
Introduction

Head and neck squamous cell carcinoma (HNSCC), encompassing an estimated 51,540 new cases in the United States in 2018 [1], represents an aggressive group of malignancies arising from various subsites in the head and neck region. Management of these cancers usually entails primary surgery followed by (chemo)radiotherapy or definitive (chemo)radiotherapy. In recent years, human papillomavirus (HPV) infection has been shown to be a strong, independent risk factor for oropharyngeal cancer [2], creating great interest in developing strategies for its eradication. Our data suggests that miR-125a-5p acts as a tumor suppressor miRNA, has potential as a diagnostic tool and may be a potential therapeutic target for the management and treatment of squamous cell carcinoma of the head and neck.

Material and Methods

MicroRNA Microarray Analysis

Total RNA was extracted from HNSCC patient samples treated in a prospective clinical trial evaluating the role of postoperative radiation therapy at MD Anderson Cancer Center [8]. Total RNA was extracted using the Qiagen RNeasy Plus kit (Qiagen). MicroRNA array profiling was done using Exiqon platform (Qiagen), with the miRCURY LNA microRNA Spike-in miRNA kit (Qiagen), used as a control. Then, labeled cRNA was hybridized on miRCURY LNA microRNA array (Qiagen), 7th generation slide, using Agilent chambers (Agilent Technologies, Santa Clara, CA). The hybridized slides were then scanned using the Tecan PowerScanner (Tecan US), and features were extracted using Arrayit ImaGene 9 (Arrayit Corporation) software for further analysis.

Survival Analysis of miR-125a-5p in The Cancer Genome Atlas

The OncoLnc tool (http://www.oncolnc.org) [9] was utilized to correlate miR-125a-5p expression in head and neck squamous cell carcinoma in The Cancer Genome Atlas and with the survival, using a 50th percentile cutoff was used to dichotomize the expression level of miR-125a-5p. Data was visualized using GraphPad Prism (GraphPad Software).

Target mRNA Expression Analysis in The Cancer Genome Atlas

The UALCAN tool (http://ualcan.path.uab.edu) [10] was utilized to assist in performing subgroup analysis of RNA-seq expression from the head and neck studies in The Cancer Genome Atlas. Expression levels of ERBB2, TXNRD1, and EIF4EBP1 were evaluated based on individual cancer stages, comparing mRNA expression levels to that of normal tissue. Data was visualized using GraphPad Prism (GraphPad).

microRNA Binding Site Analysis

To analyze the potential miRNA binding site of putative mRNA targets of miR-125a-5p, publically available miRNA prediction web tools were utilized, including DIANA-microT [11], miRANDA-miRSVR [12], MirTarget2 [13], and TargetScan [14].

Cell Culture

HN5 and UM-SCC-22B squamous cell carcinoma were cultured in Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Atlas Biologicals) and penicillin/streptomycin (Sigma-Aldrich). Cells were cultured in a humidified atmosphere of 5% CO2 at 37 °C.

microRNA Transfection

Cells were transiently transfected with 25 nM of control miRNA, miR-125a-5p mimics, or miR-125a-5p antisense inhibitors (Thermo-Fisher) using Lipofectamine RNAiMAX (Invitrogen) using the reverse transfection protocol and were harvested after 72 hours for analysis.

Plasmid DNA Transfection

pcDNA3 vector (ThermoFisher) and pcDNA3-ERBB2 (Addgene) were transfected into cells using Lipofectamine 2000 transfection reagent (ThermoFisher). The pcDNA3-ERBB2 construct was previously constructed and described [15].
**mRNA Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)**

Total RNA was extracted using the TRIzol reagent, per protocol (Invitrogen) and resuspended in nuclease-free water (Ambion). Complementary DNA (cDNA) was synthesized using Applied Biosystems High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time PCR amplification was performed using the Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad), with TaqMan primer/probes sets from Applied Biosystems (Supplementary Table 1). TaqMan Fast Advanced Master Mix (Applied Biosystems) was utilized for real-time PCR amplification. The data was analyzed using the $2^{\Delta\Delta Ct}$ method [16], using the ACTB mRNA as an endogenous control.

**microRNA Quantitative Real-Time Polymerase Chain Reaction**

microRNA transfection levels were assessed using the miRCURY LNA miRNA PCR System (Qiagen), per manufacturer’s directions. The real-time PCR amplification was performed, using the PCR primer sets (Supplementary File 1) for hsa-miR-125a-5p and U6 snRNA, as an internal control. Real-time PCR amplification was performed on the Bio-Rad CFX96 Real-Time PCR Detection System (Bio-Rad). The data was analyzed using the $2^{\Delta\Delta Ct}$ method [16], using the U6 snRNA as an endogenous control.

**miRNA Target Validation Assay**

To validate putative mRNA targets of miR-125a-5p, we utilized an affinity purification that has been previously described [17]. In brief, synthetic microRNAs of miR-125a-5p and miR-551a, used as a non-specific control, was biotinylated at the 3’ end of the RNA. Then, the biotinylated microRNAs were transfected into HN5 cells at a concentration of 50 nM for 48 hours. After lysis, streptavidin-sepharose beads were used to bind and recover biotinylated microRNA: mRNA complexes, and RNA was recovered using TRIzol reagent (Invitrogen). microRNA binding to biotinylated microRNA was then quantified using qRT-PCR.

**Western Blot**

Whole cell extracts were extracted using standard RIPA (radioimmunoprecipitation assay) buffer, containing SigmaFAST protease inhibitor cocktail tablet (Sigma-Aldrich). Laemmli 6x sodium dodecyl sulfate (SDS) protein loading buffer, containing 5% β-mercaptoethanol, was used for sample preparation followed by boiling the sample to a temperature of 95° Celsius for 5 minutes. A 4–20% Mini-PROTEAN TGX precast protein gel was used for electrophoresis, in Tris-glycine-SDS running buffer followed by a semi-dry transfer to PVDF membrane (Bio-Rad) with the Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad). The membrane was probed using antibodies obtained from Cell Signaling Technology as listed in Supplementary File 1. Peroxidase-linked secondary antibodies targeted against rabbit (catalog number NA934) or mouse (catalog number NA931) antibodies were obtained from GE Healthcare Life Sciences. Electrochemiluminescence was generated with the Pierce Electrochemiluminescence (ECL) Western Blotting Substrate (ThermoFisher) and detected and quantitated on the FluorChem M system (ProteinSimple).

**Cell Proliferation and Viability**

Transfected cells were harvested after 72 hours of transfection in 24-well tissue culture-grade plate. For cell proliferation, cell counts were quantified using the Z2 Coulter Counter Analyzer (Beckman Coulter). For cell viability, transfected cells were harvested after 72 hours of transfection, and cell viability was assayed using the CellTiter-Glo reagent, according to manufacturer’s instructions (Promega). Luminescence was measured using the POLARStar OPTIMA multi-mode plate reader (BMG Labtech).

**Cell Cycle Analysis**

Cell cycle was analyzed by propidium iodide staining of DNA content. In brief, cells were harvested and resuspended in phosphate-buffered solution (PBS) (Sigma-Aldrich). Fixation of cells was performed by added resuspended cells dropwise into 200 proof ethanol and incubated on ice for 30 minutes. The cells were then pelleted by centrifugation at 1000 rpm for five minutes. The pelleted cells were then resuspended in a PBS solution, containing 20 μg/mL of RNase A, 0.1% (vol/vol) of Triton X-100, and 20 μg/mL of propidium iodide. The cells were then incubated at room temperature for 15 minutes. The cells were then analyzed on the FlowSight Imaging Flow Cytometry and IDEAS software package (Amnis Corporation).

**In vitro Scratch Assay**

Cells were grown and transfected in a 24-well tissue culture-grade plate to approximately 75% confluence. After 72 hours of transfection, a scratch was made using a P200 pipet tip, with an outer diameter of 1.2 mm. After 48 hours, the cells were fixed and stained with a solution of 6.0% (vol/vol) glutaraldehyde and 0.5% crystal violet (wt/vol) in water. Microscopy and measurement of the wound closure was performed with the Evos XL Cell Imaging System (ThermoFisher).

**In Vitro Invasion Assay**

Cells were transfected in 60 mm tissue culture plates for 24 hours. Harvested cells were counted on the Z2 Coulter Counter Analyzer (Beckman Coulter). Cells were then resuspended in Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) without serum. The resuspended cells were then pipetted into a Corning BioCoat Matrigel Invasion Chamber (ThermoFisher), 8 μm pore size, in 24-well tissue culture-grade plates. Dulbecco’s Modified Eagle Medium (Sigma-Aldrich) supplemented with 10% FBS (Atlas Biologicals) was placed in the well of the plate as a chemo-attractant. After 24 hours, non-invading cells were removed using a cotton-tipped swab. Invasive cells, embedded into the Matrigel, was fixed using 70% ethanol then stained with a 0.5% crystal violet solution. Microscopy was performed with the Evos XL Cell Imaging System (ThermoFisher). Cells were counted in five fields of view at 10x magnification and then averaged as cells per 10x field.

**Clonogenic Assay**

Cells were transfected in 60 mm tissue culture plates for 24 hours. Cells were then harvested with trypsin–EDTA solution (Sigma-Aldrich) then counted on the Z2 Coulter Counter Analyzer (Beckman Coulter). Cells were diluted to the appropriate concentration, and then cells were plated on 60 mm tissue culture plates. Ionizing radiation was delivered using the Mark II 137Cs irradiator (JL Shepherd & Associates) at a dose rate of 3.47 Gy per minute. The dosimetry was measured using an ion chamber, calibrated with a National Institute of Standards and Technology traceable source. After 2 weeks, cells were fixed and stained with a solution of 6.0%...
Numbers of colonies formed

Surviving fraction = \frac{\text{Numbers of colonies formed}}{\text{Numbers of colonies seeded} \times \text{plating efficiency}}

Survival curves were generated using GraphPad Prism (GraphPad Software) on a log-linear graph with surviving fractions as a function of ionizing radiation dose, in Gray.

**Immunofluorescence of γH2AX and 53BP1 foci**

Cells were reverse transfected onto 8-well chamber slides (Nunc) for 24 hours. Ionizing radiation was delivered using the Mark II 137Cs irradiator (JL Shepherd & Associates) at a dose rate of 3.47 Gy per minute for a dose of 0, 1, or 2 Gy. Fixation was performed with 4% paraformaldehyde in PBS for 20 minutes at room temperature. The cells were permeabilized with PBS containing 0.5% Triton X-100 on ice for 10 minutes followed by blocking with 5% goat serum in PBS overnight at 4 °C. Rabbit anti-53BP1 antibody and mouse anti-γH2AX antibody (Supplementary File 1) were incubated, at 1:500 dilution in 5% goat serum (ThermoFisher) in PBS, with the cells for 2 hours at room temperature. Then, the cells were incubated with Alexa Fluor 488 goat anti-rabbit secondary antibody (Invitrogen, catalog number: A-11008) and Alexa Fluor 555 goat anti-mouse secondary antibody (Invitrogen, catalog number: A-21422) diluted at a concentration of 1:500 diluted in 1% bovine serum albumin and 2.5% goat serum in PBS and incubated for 1 hour in the dark. PBS was used for washing between each step. Fluoroshield mounting medium (Sigma-Aldrich) containing 4′,6-diamidino-2-phenylindole (DAPI) was used for mounting. Colocalized foci was visualized on the Zeiss Axio Imager 2 microscope (Carl Zeiss Microscopy) and analyzed using the ImageJ image processing program (National Institutes of Health).

**BrdU Immunofluorescence Assay**

Cells were reverse transfected onto 8-well chamber slides (Nunc) for 24 hours. Fresh 5-bromo-2′-deoxyuridine (BrdU) stock solution (BD Biosciences) was made by diluting BrdU into water for a final concentration of 10 mM. BrdU was further diluted into fresh growth medium (BD Biosciences) made by diluting BrdU into water for a final concentration of 10 mM. BrdU was further diluted into fresh growth medium was then removed, and the cells were incubated with Alexa Fluor 488 goat anti-rabbit secondary antibody diluted at a concentration of 1:500 in 1% bovine serum albumin in PBS for 1 hour in the dark at room temperature. PBS was used for washing between each step. Cells were then mounted in Fluoroshield mounting medium (Sigma-Aldrich) containing 4′,6-diamidino-2-phenylindole (DAPI). 5-bromo-2′-deoxyuridine-positive cells were visualized and analyzed as described above.

**Results**

**Decreased Levels of miR-125a-5p Is Associated With Locoregional Recurrence in Advanced Head and Neck Squamous Cell Carcinoma**

We first utilized microRNA profiling using microarrays to identify expression of miRNAs that are associated with local recurrence using patient samples obtained from a prospective study evaluating pathologic risk features, total combined treatment duration, and post-operative radiation therapy, which 288 registered patients with high-risk, locally advanced disease [8]. Our results reveal that in patients who developed a local recurrence, there was an associated decreased in miR-125a-5p expression, compared to patients who did not have evidence of disease (P = .0036), out of a total of 77 evaluable patient samples analyzed (Fig. 1A). Clinico-pathologic characteristics of this patient cohort is shown in Supplementary Table 1. This results suggests that miR-125a-5p is a potential marker associating low expression levels with local recurrence. We then performed chi-squared analysis of our patient cohorts, comparing clinicopathologic risk factors such as age, tumor subsite, T stage, N stage, extracapsular extension, and surgical margin status (Supplementary Table 2). We did not observe any differences in between patients with no evidence of disease and patients with locoregional recurrence with the aforementioned risk factors, suggesting that miR-125a-5p expression is the only analyzed risk factor that is associated with locoregional recurrence.

**Decreased levels of miR-125a-5p in head and neck squamous cell carcinoma is associated with a poor prognosis.** Using OncoLnc [9], which links RNA-seq expression data with survival in The Cancer Genome Atlas [18] (https://cancergenome.nih.gov), we find that patients with low levels of miR-125a-5p is associated with a worse overall survival than patients with high levels of miR-125a-5p (P = .006) (Figure 1B). This suggests that miR-125a-5p may act as a tumor suppressor miRNA and that decreased miR-125a-5p levels can lead to a more aggressive phenotype and clinical outcome. Univariable Cox regression analysis did not identify any other variable in our cohort that affected survival (Supplementary Table 3), suggesting that decreased miR-125a-5p expression is associated with poor prognosis.

**miR-125a-5p Modulates Cell Proliferation by Regulating the G1/S Transition of the Cell Cycle**

We hypothesize that miR-125a-5p functions as a tumor suppressor miRNA, and to test this hypothesis, we studied the effect of miR-125a-5p on cell proliferation in vitro. We transfected miR-125a-5p mimics into HN5 and UM-SCC-22B head and neck squamous cell carcinoma cell lines. We confirmed the transfection of miRNA mimics into each cell line (Supplementary Fig. 1). We observed that there is decreased cell proliferation in both HN5 and UM-SCC-22B cell lines when miR-125a-5p mimics are transfected, compared to the negative control miRNA, using an in vitro cell counting assay (Figure 2A). We corroborated the result by performing a cell viability assay with the CellTiter-Glo luminescent reagent, which showed decreased cell viability with transfection of miR-125a-5p, compared to cells transfected with control miRNA (Figure 2B).
We then performed cell cycle analysis to further investigate the effect of miR-125a-5p on cell proliferation and cell cycle regulation. In both HN5 and UM-SCC-22B cell lines, there was an increase in the proportion of cells in the G1 phase with transfection of miR-125a-5p, with a concomitant proportion of cells decreased in S phase, in HN5 and UM-SCC-22B cells with miR-125a-5p mimic transfected, compared to controls (Figure 2C). To further investigate the role of miR-125a-5p on cell cycle progression, we found that there was an increase in p27 protein expression with transfection of miR-125a-5p mimics, compared to control cells, in both tested cell lines (Figure 2D). We also performed a BrdU incorporation immunofluorescence assay that did not show any changes with DNA synthesis with transfection of miR-125a-5p in either cell lines (Figure 2, E and F). We also did not see any effects from apoptosis or autophagy that can affect cell proliferation assays (Supplementary Fig. 2). Our data suggests that miR-125a-5p affects cell proliferation by regulating transit through the G1/S transition through p27 but does not affect DNA synthesis.

miR-125a-5p Regulates Cell Migration and Invasion In Vitro

Head and neck squamous cell carcinoma are aggressive malignancies that are locally destructive with high rates of metastatic spread to regional lymph nodes. Histologically, worse pattern of invasion is an independent predictor of locoregional recurrence, in patients with low-stage oral cavity squamous cell carcinoma [19]. We performed an in vitro cell migration scratch assay and found that transfection of miR-125a-5p into both HN5 and UM-SCC-22B cell lines resulted in decreased cell migratory ability, as compared to the control miRNA (Figure 3, A and B). We then performed an in vitro transwell invasion assay using Matrigel extracellular matrix. We observed that there was decreased in vitro cell invasion with transfection of miR-125a-5p, compared to the control miRNA (Figure 3, C and D).

miR-125a-5p Modulates Sensitivity to Ionizing Radiation

Radiation therapy is a key modality for the management of head and neck squamous cell carcinoma, either in the definitive, adjuvant, or recurrent setting. To evaluate the effect of miR-125a-5p on response to ionizing radiation, an in vitro clonogenic assay was performed. With transfection of miR-125a-5p mimics, we observed a decrease in surviving fraction in response to ionizing radiation, compared to the control miRNA, in HN5 (Figure 4A) and UM-SCC-22B cells (Figure 4B). Similarly, when miR-125a-5p is inhibited using antisense inhibitors, the cells are rendered resistant to ionizing radiation. A γH2AX and 53BP1 foci formation assay was then performed to determine the effect of miR-125a-5p on double-stranded DNA break repair kinetics in response to ionizing radiation, in HN5 and UM-SCC-22B cell lines. After 1 Gy of ionizing radiation, there was an appreciable increase in γH2AX and 53BP1 colocalized foci at 1, 4, and 24 hours (Figure 5 and Supplementary Fig. 3), in both cell lines with miR-125a-5p, compared to the control miRNA. There was no difference in the number of colocalized 53BP1 and γH2AX foci at 48 hours, with the number of foci per nucleus returning to baseline levels. There was no increase in double-stranded DNA break formation without any ionizing radiation, in response to transfection of miR-125a-5p, suggesting that there is no contribution by miR-125a-5p by itself to double-stranded DNA damage (Figure 5 and Supplementary Fig. 4). This effect is also seen in response to 2 Gy of ionizing radiation (Supplementary Fig. 5 and 6). Our data suggests that miR-125a-5p has a role in modulating sensitivity to ionizing radiation in head and neck squamous cell carcinoma through delaying resolution of double-stranded DNA breaks.
miR-125a-5p is a tumor suppressor miRNA in head and neck cancer

Vo et al.  Neoplasia  Vol. 21, No. 9, 2019

**A**

![Graph A](image)

**B**

![Graph B](image)

**C**

![Graph C](image)

**D**

![Graph D](image)

**E**

![Images E](image)

**F**

![Images F](image)
miR-125a-5p Targets the mRNA of ERBB2, EIF4EBP1, and TXNRD1 in Head and Neck Squamous Cell Carcinoma

We hypothesized that miR-125a-5p acts as a tumor suppressor miRNA by targeting oncogenic mRNAs, and that through loss or downregulation of miR-125a-5p, there is a resultant increase in the expression of various oncogenic proteins. Therefore, to better understand how miR-125a-5p exerts its effects, we sought to identify mRNA targets of miR-125a-5p.

In order to identify putative mRNA targets of miR-125a-5p, we identified mRNAs that were upregulated in an mRNA expression microarray dataset that was generated from patient tumor samples that were collected in a prospective trial evaluating pathologic risk features, BA

Figure 3. miR-125a-5p regulates cell migratory and invasive ability in vitro. Transfection of miR-125a-5p into HN5 (A) and UM-SCC-22B (B) cell lines results in decreased wound healing, compared to control miRNA, in an in vitro wound healing assay. Cells were fixed in glutaraldehyde and stained with crystal violet. Brightfield microscopic images were taken with a 10x objective. Cell invasion was assessed with a Matrigel invasive chamber. Cells were transfected with miRNA mimics and then placed into the chamber for a period of 24 hours. The cells that were embedded in the Matrigel were stained using crystal violet and counted using brightfield microscopy with a 10x objective. There were decreased cells invading into the Matrigel with transfection of miR-125a-5p mimic, compared to the control miRNA, in both HN5 (C) and UM-SCC-22B (D) cells. Data were analyzed with the Student's t-test and are presented as the mean ± standard deviation. The in vitro scratch assay was carried out in triplicate. Five 10x fields were analyzed for the in vitro invasion assay.

miR-125a-5p modulates cell proliferation in vitro via regulating the cell cycle at the G1/S transition by increasing p27 expression. (A) Transfection of miR-125a-5p into HN5 and UM-SCC-22B cell lines results in decreased cell counts, compared to transfection of a control miRNA. (B) Transfection of miR-125a-5p into HN5 and UM-SCC-22B cell lines results in luminenscence, using the CellTiter-Glo Assay (Promega), compared to transfection of a control miRNA. (C) Transfection of miR-125a-5p into HN5 and UM-SCC-22B cell lines results in increased proportion of cells in the G1 phase with a concomitant decrease in percentage of cells in S phase, compared to control miRNA transfection, as determined by the propidium iodide cell cycle assay. Cell cycle analysis was performed on the FlowSight Imaging Flow Cytometer (Amnis). (D) Western blotting of p27 protein shows increased expression of p27 after transfection of miR-125a-5p mimic, as compared to control miRNA. 5-bromo-2'-deoxyuridine (BrdU) assay reveals that miR-125a-5p does not affect DNA synthesis in HN5 (E) and UM-SCC-22B (F) cell lines. Data were analyzed with the Student's t-test and are presented as the mean ± standard deviation. Experiment was carried out in triplicate with the BrdU DNA synthesis assay performed in quintuplicate.
miR-125a-5p is a tumor suppressor miRNA in head and neck cancer  
Vo et al. Neoplasia Vol. 21, No. 9, 2019

![Graphs A and B showing survival fraction against radiation dose for HN5 and UM-SCC-22B cell lines transfected with miR-125a-5p mimic, miR-125a-5p inhibitor, and control miRNA.](Graphs.png)

**Figure 4.** miR-125a-5p modulates sensitivity to ionizing radiation. HN5 (A) and UM-SCC-22B (B) cell lines were transfected with miR-125a-5p mimic, miR-125a-5p inhibitors, or control miRNA. Cells were then harvested and plated. Four hours after plating, cells were then treated increasing doses of ionizing radiation using a Cesium-137 irradiator. After two weeks of growth, colonies, consisting of 50 cells or more, were fixed with a solution of glutaraldehyde and stained with crystal violet. Colonies were then counted and plotted with surviving fraction as a function of radiation dose. Transfection of miR-125a-5p mimics results in increased sensitivity to ionizing radiation, compared to the cells transfected with control miRNA, while transfection of miR-125a-5p antisense inhibitors rendered the cells more resistant to ionizing radiation. Experiment was carried out in triplicate. Data were analyzed with the Student's t-test at each ionizing radiation dose level and are presented as the mean ± standard deviation with * signifying \( P \leq 0.05 \), ** signifying \( P \leq 0.01 \), and *** signifying \( P \leq 0.001 \).

We then mined through our microarray profiling data and observed statistically significant increase in mRNA expression levels of these target mRNAs in our microarray profiled patients with locoregional recurrence, compared to patients with no evidence of disease (Figure 6A), the inverse of what was observed with miR-125a-5p expression (Figure 1). We then mined through The Cancer Genome Atlas, using the UALCAN web tool (ualcan.path.uab.edu) and found that that head and neck squamous cell carcinoma exhibited increasing mRNA levels of TXNRD1 and EIF4EBP1 with more advanced clinical stage of disease presentation (Figure 6B and Supplementary Table 5). Analysis of the 3' untranslated region of TXNRD1 and EIF4EBP1 mRNA reveals putative, canonical binding sites for miR-125a-5p. (Figure 6C). To evaluate whether the mRNA of TXNRD1 and EIF4EBP1 physically binds to miR-125a-5p, we performed a biotin-streptavidin pulldown assay [17] to confirm the targeting of EIF4EBP1 and TXNRD1 by miR-125a-5p, using a biotinylated synthetic construct of miR-125a-5p. We found that both putative mRNA targets are bound to biotinylated miR-125a-5p, as measured by qRT-PCR, but not biotinylated miR-551a, which was used as a negative, nonspecific control, confirming the in silico prediction of the binding of the target mRNA to miR-125a-5p (Figure 6D). We then transfected miR-125a-5p into HN5 and UM-SCC-22B cell lines and then blotted for 4E-BP1 and TXNRD1 protein. We found that miR-125a-5p was able to repress protein levels of TXNRD1 and EIF4EBP1 mRNA targets (Figure 6E). We also measured mRNA levels using qRT-PCR and found that the mRNA levels of TXNRD1 were decreased after miR-125a-5p transfection, as compared to the control miRNA, suggesting that miR-125a-5p, at least in part, controls expression of TXNRD1, through mRNA destabilization (Figure 6F). However, when we evaluated the mRNA expression of EIF4EBP1, there was no statistically difference between the miR-125a-5p mimic and control miRNA (Figure 6G), signifying that decrease in protein level as seen in the immunoblotting analysis is mainly through translational repression, rather than mRNA destabilization.

We also investigated ERBB2 mRNA as a target of miR-125a-5p, as it is an important signaling molecule in many cancers, including head and neck cancer. Similar to TXNRD1 and EIF4EBP1, we observed an increased in mRNA expression in patients who had a locoregional recurrence, compared to patients with no evidence of disease (Figure 7A). We then analyzed the 3' untranslated region of ERBB2 and found that it contains a binding site for miR-125a-5p (Figure 7B). Using an in vitro pulldown assay, we found that the ERBB2 mRNA preferentially binds to biotinylated miR-125a-5p, compared to the nonspecific, biotinylated miR-551a (Figure 7C). Transfection of miR-125a-5p resulted in decreased ERBB2 protein expression, compared to control miRNA transfection (Figure 7D), likely in part to decreased ERBB2 mRNA expression (Figure 7E). In addition, overexpression of ERBB2 using an expression plasmid construct resulted in increased cell proliferation in HN5 and UM-SCC-22B cells, compared to the empty vector pcDNA3 control (Figure 7F). We observed increased PI3K-AKT signaling with a concomitant decrease in p27Kip1 protein expression (Supplementary Fig. 7), and we also found that overexpression of ERBB2 results in increased resistance to ionizing radiation, compared to transfection of total combined treatment duration, and post-operative radiation therapy [8]. Using a cut-off of two-fold increase in mRNA expression levels, we identified 1249 mRNAs that were upregulated in tumor samples, compared to normal tissue. We then utilized four miRNA prediction algorithms, DIANA-microT [11], miRANDA-miRsvr [12], MirTarget2 [13], and TargetScan [14], to identify subsets of the upregulated mRNAs that contain well-conserved, low-binding energy binding sites for miR-125a-5p. We focused on mRNAs that were predicted in at least two prediction algorithms (Supplementary Table 2). From this list of 29 putative target mRNAs, we selected three mRNAs for further study as they have been previously implicated in head and neck squamous cell carcinoma, ERBB2 [20], EIF4EBP1 [21], and TXNRD1 [22].
a control cDNA plasmid, suggesting that miR-125a-5p modulates sensitivity to radiation therapy, in part, through ERBB2 (Figure 7).

**Discussion**

With the increasing amount of data accumulating from systems-based efforts such as next generation sequencing, microRNA in cancer has created a great amount of interest as its study can allow for interrogation of the underlying biology in cancer, revealing novel mechanisms in tumorigenesis, as well as the potential development of markers for diagnostic and therapeutic applications. However, given the amount of data created, a greater amount of effort is required to validate the significance of potential genes or non-coding RNAs, such as miRNAs, in cancer. Regulation of gene expression is finely regulated in normal cells, and aberrations in gene expression, such as in cancer, are dependent on the cell type and context. Specifically, the regulation of a single mRNA at the post-transcriptional level can be governed by changes in secondary structure, binding by RNA-binding proteins, and miRNAs, requiring genomic approaches and computational methods for study and analysis [6]. Nonetheless, it is very important to experimentally validate the significance of miRNAs and their posited roles in tumorigenesis. In our study, we establish a defined role of miR-125a-5p as a tumor suppressor miRNA in head and neck squamous cell carcinoma, whose basis was from a previous study from our group showing that miR-125a-5p is downregulated in HNSCC, as compared to normal tissue [7].

In our study, we demonstrate that miR-125a-5p functions as a tumor suppressor microRNA (miRNA) in head and neck squamous cell carcinoma (HNSCC) through regulating cell proliferation and mediating sensitivity to ionizing radiation. Our report suggests potential clinical implications as radiotherapy is the backbone of treatment for patients with head and neck cancer, commonly used either in the definitive or adjuvant setting. The tumor suppressive

![Figure 5. miR-125a-5p reduces rate of resolution of double-stranded DNA break in response to ionizing radiation. HN5 and UM-SCC-22B cell lines were transfected with miR-125a-5p mimic or control miRNA then exposed to ionizing radiation at 1 and 0 Gy, using a Cesium-137 source. Cells were then stained at specific time points after irradiation and stained for 53BP1, γH2AX, and DAPI, a nuclear stain. Secondary antibodies were then used to fluorescently tag the bound antibodies to 53BP1 and γH2AX with Alexa Fluor 488 and Alexa Fluor 555, respectively. Colocalized foci were then counted and displayed as the mean ± standard error of the mean. The data at each time point was analyzed using the Student’s t-test, with * signifying \( P \leq .05 \) and ** signifying \( P \leq .01 \). There was a significant increase in colocalized 53BP1 and γH2AX foci with miR-125a-5p, compared to the control miRNA, at 4 hours after irradiation with 1 Gy that persisted at 24 hours.](image-url)
miR-125a-5p is a tumor suppressor miRNA in head and neck cancer

Vo et al.

Neoplasia Vol. 21, No. 9, 2019

miR-125a-5p

**A**

- **TXNRD1**
  - Normalized signal intensity (log)
  - p = 0.0444

- **EIF4EBP1**
  - Normalized signal intensity (log)
  - p = 0.0104

**B**

- **TXNRD1**
  - Transcript per million
  - Normal
  - Stage I
  - Stage II
  - Stage III
  - Stage IV
  - p = 0.03

- **EIF4EBP1**
  - Transcript per million
  - Normal
  - Stage I
  - Stage II
  - Stage III
  - Stage IV
  - p = 0.01

**C**

- **TXNRD1 mRNA**
  - 5'...
  - AGUGUCAAAUUUCCCAGAAGGCCCU

- **miR-125a-5p**
  - 3'
  - AGUGUCAAAUUUCCCAGAAGGCCCU

- **EIF4EBP1 mRNA**
  - 5'...
  - AGUGUCAAAUUUCCCAGAAGGCCCU

- **miR-125a-5p**
  - 3'
  - AGUGUCAAAUUUCCCAGAAGGCCCU

**D**

- **TXNRD1**
  - Relative mRNA level
  - 0
  - 10
  - 20
  - 30
  - 40
  - p < 0.0001

- **EIF4EBP1**
  - Relative mRNA level
  - 0
  - 10
  - 20
  - 30
  - 40
  - p < 0.0001

**E**

- **HN5**
  - Control miRNA
  - miR-125a-5p mimic
  - TXNRD1
  - β-actin
  - Relative expression
  - 1.00
  - 0.71
  - 1.00
  - 0.74

- **UM-SCC-22B**
  - Control miRNA
  - miR-125a-5p mimic
  - TXNRD1
  - β-actin
  - Relative expression
  - 1.00
  - 0.48
  - 1.00
  - 0.64

**F**

- **HN5 - TXNRD1**
  - Relative mRNA expression
  - 0.0
  - 0.5
  - 1.0
  - 1.5
  - p = 0.01

- **UM-SCC-22B - TXNRD1**
  - Relative mRNA expression
  - 0.0
  - 0.5
  - 1.0
  - 1.5
  - p = 0.002

**G**

- **HN5 - EIF4EBP1**
  - Relative mRNA expression
  - 0.0
  - 0.5
  - 1.0
  - 1.5
  - p = 0.14

- **UM-SCC-22B - EIF4EBP1**
  - Relative mRNA expression
  - 0.0
  - 0.5
  - 1.0
  - 1.5
  - p = 0.92
function of miR-125a-5p in HNSCC, as demonstrated by our results, is concordant with previous studies in other malignancies, such as lung cancer [23], breast cancer [24], multiple myeloma [25], gastric cancer [26], hepatocellular carcinoma [27], chronic lymphocytic leukemia [28], nasopharyngeal carcinoma [29], glioblastoma [30], colon cancer [31], prostate cancer [32], cervical carcinoma [33], and thyroid cancer [34], implicating miR-125-5p as a general tumor suppressor miRNA, across a broad spectrum of malignancies.

This report has also identified three mRNA targets of miR-125a-5p in head and neck squamous cell carcinoma, specifically, ERBB2, which encodes for the erbB-2, otherwise known as HER2/neu, receptor tyrosine kinase, TXNRD1, which encodes for thioredoxin reductase 1, and EIF4EBP1, which encodes for the 4E-BP1 translation initiation factor. ERBB2/HER2 is a receptor tyrosine kinase that belongs to the ERBB family and is commonly amplified in breast cancer [35] or gastric cancer [36], can result in homodimerization, enhancing downstream signaling, increasing cell proliferation, decreased apoptosis, and increased cell migratory and invasive abilities [37]. ERBB2 has also emerged a potent target of trastuzumab and pertuzumab in breast cancer [38]. Our functional assays evaluating cell proliferation and sensitivity to ionization radiation suggest that miR-125a-5p acts, in part, through ERBB2 [39,40]. Thioredoxin reductase 1, a selenocysteine-containing protein, is a major component in the reduction–oxidation (redox) that is a critical system maintaining cellular homeostasis and normal function, including cell proliferation, protection from oxidative stress, and regulating the extracellular redox state [41]. Thioredoxin reductase 1 is found to be overexpressed in many human cancers [42], leading to resistance to ionizing radiation, likely through increased AP-1 DNA-binding activity, a transcription factor that contain redox-sensitive cysteine motifs [43]. Targeting thioredoxin reductase 1 with the plant polyphenol, curcumin, can induce radiosensitization in squamous carcinoma cells [44]. Another mRNA target of miR-125a-5p reported in our study is EIF4EBP1, which encodes for the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). Normally, 4E-BP1 is phosphorylated, along with S6 kinase 1 (S6K1), by mTOR complex 1 (mTORC1), in response of upstream growth factor signals to stimulate protein synthesis [45]. 4E-BP1 can promote the translation of cap-independent mRNAs over cap-dependent mRNAs, especially in times of cellular stress, such as in the case of Bcl-2, to promote cellular survival [46]. Overexpression of 4E-BP1 occurs in many types of cancer, including breast cancer, colorectal cancer, kidney cancer, and lung cancer and is thought to acts a tumor promoter [47]. Our data suggests an additional mechanism for increased 4E-BP1 levels through a miR-125a-5p-mediated, post-transcriptional mechanism, in addition to the previously described mechanisms of gene amplification of the 11q13 chromosomal region [48]. Our study highlights the potential of understanding miRNA biology to reveal important targets and dissect influential mechanisms in head and neck cancer.

Perhaps, the more intriguing aspects of studying miRNA in cancer is in its value for diagnostic and therapeutic applications. There has been great interest in using miRNAs as a therapeutic strategy. Recently, in a phase I study of liposomal miR-34a mimic, dubbed MRX34, many patients enrolled on the study experienced adverse effects, which was suspected to be due to infusion-related intolerability, limiting its potential clinical utility [49]. However, the potential for RNA interference-based therapeutics continues to exist through the recent Breakthrough Therapy Designation from the U.S. Food and Drug Administration for patisiran, an RNA interference therapeutic agent, for the treatment of hereditary transthyretin amyloidosis with polyneuropathy based on recent phase III study demonstrating improved neurological outcomes [50]. More interestingly, there has been increasing interesting in incorporating genomics into clinical practice, such as the use of gene expression profiling in the management of early stage breast cancer to guide the decision of use of adjuvant systemic therapy [51] or genomic classifiers to predict for metastatic disease in patients with prostate cancer post-prostatectomy [52]. In nasopharyngeal cancer, the detection of Epstein–Barr virus DNA after primary therapy with chemotherapy and radiotherapy was associated with worse survival than patients with undetectable levels of Epstein–Barr virus DNA [53], suggesting that there is a subset of patients that can potentially benefit from treatment escalation, which is the basis of the currently accruing NRG Oncology trial, NRG-HN-001.

Our study suggests that miR-125a-5p has a molecularly pivotal role in head and neck cancer, and lower expression of miR-125a-5p is associated with increased risk of locoregional recurrence, proposing that

Figure 6. Putative mRNA targets of miR-125a-5p are associated with locoregional recurrence, are upregulated in advanced squamous cell carcinoma of the head and neck, compared to normal tissue and directly targets TXNRD1 and EIF4EBP1 mRNA to downregulate protein expression. (A) Messenger RNA microarray analysis from patient tumor samples collected from a prospective trial of postoperative radiation therapy was performed, revealing an association of local recurrence with increased mRNA expression of putative target mRNAs, TXNRD1 and EIF4EBP1, compared to patients with no evidence of disease. The data were analyzed with the Student's t-test and is presented as the mean ± standard error of the mean. (B) mRNA expression levels for EIF4EBP1, which encodes for the 4E-BP1, were analyzed with the Student's t-test and are presented as the mean ± standard deviation. Experiment was carried out in triplicate.

Our study suggests that miR-125a-5p has a molecularly pivotal role in head and neck cancer, and lower expression of miR-125a-5p is associated with increased risk of locoregional recurrence, proposing that
Figure 7. The putative mRNA target of miR-125a-5p, \textit{ERBB2}, is associated with locoregional recurrence and modulates sensitivity to ionizing radiation. (A) Messenger RNA microarray analysis from patient tumor samples collected from a prospective trial of postoperative radiation therapy was performed, revealing an association of local recurrence with increased mRNA expression of putative target mRNA, \textit{ERBB2}, compared to patients with no evidence of disease. The data were analyzed with the Student's t-test and is presented as the mean ± standard error of the mean. (B) Predicted binding sites of miR-125a-5p on the 3' untranslated region of \textit{ERBB2} mRNA. The TargetScan ([14]) was utilized to predict for the binding site based on conservation of the mRNA binding site to the miRNA seed sequence. Vertical lines show Watson-Crick base pairing between the mRNA and miRNA. (C) \textit{In vitro} pulldown assay with a synthetically biotinylated miR-125a-5p were transfected into HN5, using biotinylated miR-551a as a negative control, and then recovered using streptavidin-agarose beads, which were then washed. Recovered RNAs were analyzed using quantitative RT-PCR, which revealed that \textit{ERBB2} mRNA binds directly to miR-125a-5p, compared to the RNA species bound to miR-551a. (D) Transfection of miR-125a-5p results in decreased \textit{ERBB2} protein expression, compared to control miRNA, in HN5 and UM-SCC-22B cell lines. (E) Transfection of miR-125a-5p results in decreased \textit{ERBB2} mRNA expression, compared to control miRNA. (F) Overexpression of \textit{ERBB2} by transfection of plasmid DNA containing the coding sequence of \textit{ERBB2} (pcDNA3-\textit{ERBB2}) increases cell proliferation in HN5 and UM-SCC-22B, as measured using the CellTiter-Glo Assay (Promega), compared to transfection of an empty control plasmid (pcDNA3), measured 72 hours after transfection. The data were analyzed with the Student's t-test and is presented as the mean ± standard deviation. (G) \textit{ERBB2} overexpression increases resistance to ionizing radiation. HN5 and UM-SCC-22B cell lines were transfected with a plasmid containing an \textit{ERBB2} cDNA or control cDNA. Cells were then harvested and plated. Four hours after plating, cells were then treated increasing doses of ionizing radiation using a Cesium-137 irradiator. After 2 weeks of growth, colonies, consisting of 50 cells or more, were fixed with a solution of glutaraldehyde and stained with crystal violet. Colonies were then counted and plotted with surviving fraction as a function of radiation dose. Transfection of \textit{ERBB2} cDNA results in increased resistance to ionizing radiation, compared to the cells transfected with control cDNA plasmid. Data were analyzed with the Student's t-test at each ionizing radiation dose level and are presented as the mean ± standard deviation with * signifying \(P \leq .05\), ** signifying \(P \leq .01\), and *** signifying \(P \leq .001\).
miR-125a-5p expression can be utilized as a biomarker to individualize treatment for patients with head and neck cancer, especially those that are HPV-negative, a malignancy whose biology does not currently have any clinically defined and useful biomarker. These patients can potentially benefit from treatment escalation, for example, in the form of dose-escalated radiotherapy or use of novel and emerging systemic agents such as immunotherapies. In sum, the study of miRNAs in cancer can allow for the uncovering and discovery of novel targets in cancer as well as allow for the use biomarker-based risk stratification and response assessment to personalize cancer therapy, making the study of miRNAs even more important than before.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neo.2019.06.004.

References

[1] Siegel RL and Miller KD (2018). Jemal A (2018). Cancer statistics. CA Cancer J Clin 68, 7–30.

[2] Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DL, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, and Lu C, et al (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363, 24–35.

[3] Mirghani H, Amen F, Blanchard P, Moreau F, Guigay J, Hartl DM, and Lacau St Guiy J (2015). Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives. Int J Cancer 136, 1494–1503.

[4] Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function Cell, 116; 2004 281–297.

[5] Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10, 704–714.

[6] Balaraman M, Inglese J, and Elledge S (2014). The cell cycle is a network controlled by microRNAs. Cell 157, 305–316.

[7] Anaya J (2016). OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Computer Science 2,e67.

[8] Chandrasekhar DS, Basher B, Balasubramanayam SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, and Varambally S (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 19, 649–658.

[9] Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos I, Angopoulou MD, and Licitra L (2018). IncRNA-BI3 promotes cell invasion and biofilm formation via miR-125a-5p in head and neck cancer cells. Cancers 10, 560.

[10] Wang SC, and Tsai EM (2015). miR-125a-5p is a prognostic biomarker that predicts the progression and prognosis of non-small cell lung cancer. Cancer Invest 33, 366–374.

[11] Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos I, Angopoulou MD, and Licitra L (2018). IncRNA-BI3 promotes cell invasion and biofilm formation via miR-125a-5p in head and neck cancer cells. Cancers 10, 560.
overexpression on cell signaling networks governing proliferation and migration. 

Mol Syst Biol 2, 54.

[38] Appert-Collin A, Hubert P, Creemel G, and Bennassroune A (2015). Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol 6, 283.

[39] Swain SM, Baelde J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneweis A, and Heeson S, et al (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372, 724–734.

[40] Duru N, Fan M, Candas D, Menas C, Liu HC, Nantajit D, Wen Y, Xiao K, Eldridge A, and Chromy BA, et al (2012). HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res 18, 6634–6647.

[42] Lincoln DT, Ali Emadi EM, Tonissen KF, and Clarke FM (2003). The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res 23, 2425–2433.

[43] Arner ES and Holmgren A (2000). Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267, 6102–6109.

[44] Karimpour S, Lou J, Lin LL, Rene LM, Lagunas L, Ma X, Karra S, Bradbury CM, Markovina S, and Gowami PC, et al (2002). Thioredoxin reductase regulates AP-1 activity as well as thioredoxin nuclear localization via active cysteines in response to ionizing radiation. Oncogene 21, 6317–6327.

[45] Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, and Koumenis C (2010). Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res 70, 1941–1950.

[47] Musa J, Orth MF, Dallmayer M, Baldauf M, Pardo C, Rotblat B, Kirchner T, Leprivier G, and Grunewald TG (2016). Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis. Oncogene 35, 4675–4688.

[48] Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olson B, Hallbeck AL, and Stal O (2011). High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50, 775–787.

[49] Karimpour S, Lou J, Daccache J, Borad M, Kang YK, Sroudmore J, Smith S, Bader AG, Kim S, and Hong DS (2017). Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs 35, 180–188.

[50] Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tourne J, Schmidt HH, Coelho T, Berk JL, et al. (2016). Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 379, 11–21.

[51] Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, and Mennel RG, et al (2016). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34, 1134–1150.

[52] Spratt DE, Youssef K, Dehesi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, and Dicker AP, et al (2017). Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J Clin Oncol 35, 1991–1998.

[53] Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, and Jiang RS (2004). Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 350, 2461–2470.